Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $10,110,417.12 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 16,083 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $628.64, for a total value of $10,110,417.12. Following the sale, the chief executive officer directly owned 417,289 shares of the company’s stock, valued at $262,324,556.96. The trade was a 3.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Medpace Stock Performance

Shares of MEDP opened at $618.88 on Monday. The firm has a market cap of $17.27 billion, a P/E ratio of 36.28, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The company’s 50-day moving average price is $594.65 and its 200 day moving average price is $516.25.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. American Capital Management Inc. purchased a new stake in Medpace in the second quarter valued at $111,329,000. Focus Partners Advisor Solutions LLC purchased a new position in shares of Medpace during the second quarter worth about $1,685,000. California State Teachers Retirement System increased its position in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Medpace during the second quarter worth about $1,323,047,000. Finally, Madison Asset Management LLC purchased a new stake in shares of Medpace in the 2nd quarter valued at about $128,956,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on MEDP shares. Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. TD Cowen increased their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $595.20.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.